Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Toyota Just Electrified a Pickup Legend, but It Won’t Be Cheap - 2Fabricated statement about Malaysian national exam top scorers stokes racial sentiment
- 3Excited visitors for NASA's moon launch jockey for prime views
- 4Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- 5Boeing's troubled capsule won't carry astronauts on next space station flight
- NASA’s Artemis II mission will take an astronaut crew around the Moon – a space policy expert describes the long road to launch
- Step by step instructions to Pick the Right Web-based Degree Program
- Kate Hudson, 46, says she doesn't need long workouts to feel good
- The Main 15 Applications for Efficiency and Association
- The most effective method to Go Down Abundance through Ages with Disc Rates
- Heartfelt Objections to Visit with Your Adored One
- Yoshi mania, Happy Meals and not-so-great reviews: A small talk guide to 'The Super Mario Galaxy Movie'
- The Leonid meteor shower is peaking early this week. Here’s what to know
- Jubilant FoodWorks to scrap Dunkin’ franchise arrangement in India
